Abbott Laboratories $ABT Shares Sold by Tredje AP fonden

Tredje AP fonden reduced its stake in shares of Abbott Laboratories (NYSE:ABT) by 9.2% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 729,151 shares of the healthcare product maker’s stock after selling 74,000 shares during the quarter. Tredje AP fonden’s holdings in Abbott Laboratories were worth $97,662,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ABT. Coyle Financial Counsel LLC lifted its stake in shares of Abbott Laboratories by 6.3% in the 3rd quarter. Coyle Financial Counsel LLC now owns 6,380 shares of the healthcare product maker’s stock worth $855,000 after acquiring an additional 379 shares during the period. Raiffeisen Bank International AG raised its holdings in Abbott Laboratories by 10.1% during the third quarter. Raiffeisen Bank International AG now owns 360,514 shares of the healthcare product maker’s stock worth $47,988,000 after purchasing an additional 33,095 shares in the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its position in Abbott Laboratories by 8.0% in the third quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 31,345 shares of the healthcare product maker’s stock worth $4,198,000 after purchasing an additional 2,322 shares during the period. Dempze Nancy E boosted its stake in Abbott Laboratories by 0.7% during the 3rd quarter. Dempze Nancy E now owns 42,594 shares of the healthcare product maker’s stock valued at $5,705,000 after purchasing an additional 286 shares in the last quarter. Finally, AMG National Trust Bank increased its position in shares of Abbott Laboratories by 2.2% during the 3rd quarter. AMG National Trust Bank now owns 32,455 shares of the healthcare product maker’s stock valued at $4,347,000 after purchasing an additional 688 shares during the period. Institutional investors own 75.18% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ABT. Barclays decreased their target price on Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating for the company in a research note on Monday, February 2nd. Daiwa Securities Group cut their price target on shares of Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating for the company in a report on Friday, January 30th. Evercore lowered their price objective on shares of Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Citigroup dropped their target price on shares of Abbott Laboratories from $155.00 to $140.00 and set a “buy” rating on the stock in a report on Friday, January 23rd. Finally, The Goldman Sachs Group reduced their target price on shares of Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating for the company in a report on Friday, January 23rd. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Abbott Laboratories has an average rating of “Moderate Buy” and an average target price of $137.05.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Exact Sciences stockholders approved Abbott’s acquisition proposal (preliminary results showed >99% of votes cast and ~67% of outstanding shares represented), clearing a key shareholder hurdle and advancing Abbott’s expansion into cancer screening/diagnostics — a strategic deal that should broaden revenue mix and long-term growth prospects. Exact Sciences Stockholders Approve Acquisition by Abbott
• Positive Sentiment: Abbott’s board declared its 409th consecutive quarterly dividend at $0.63/share, reinforcing a reliable income profile that supports shareholder confidence and may attract income-oriented investors. Abbott declares 409th consecutive quarterly dividend
• Positive Sentiment: Abbott reported positive clinical results for its Amulet 360 Left Atrial Appendage (LAA) occluder presented at the AF Symposium — a favorable outcome for the company’s structural-heart/device pipeline that could support future market adoption and revenue growth in electrophysiology/cardiology. Abbott Laboratories (ABT) Announces Positive Results for Amulet 360 Left Atrial Appendage (LAA) Occlude
• Neutral Sentiment: Abbott’s board approved governance changes to streamline the board (smaller board size). This is a modest corporate-governance move that could slightly improve oversight/efficiency but is unlikely to drive material near-term earnings changes. Abbott Laboratories Streamlines Governance With Smaller Board
• Neutral Sentiment: Media comparisons (BSX vs ABT) highlight Abbott’s valuation appeal, CGM momentum and strategic deals as advantages vs. Boston Scientific — useful context for investors but not a direct corporate action. BSX vs. ABT: Which MedTech Stock is the Better Investment Now?
• Negative Sentiment: BTIG cut its price target for ABT to $140, which may temper near-term analyst-driven upside and investor enthusiasm despite the company’s strategic wins; analyst revisions can influence sentiment and trading volume. BTIG Research Cuts Abbott Laboratories (NYSE:ABT) Price Target to $140.00

Insider Activity

In other news, Director Daniel J. Starks acquired 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 4th. The stock was acquired at an average cost of $108.73 per share, for a total transaction of $1,087,300.00. Following the completion of the acquisition, the director owned 6,738,817 shares in the company, valued at approximately $732,711,572.41. The trade was a 0.15% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Trading Up 0.0%

NYSE:ABT opened at $112.21 on Friday. The stock has a market cap of $195.11 billion, a PE ratio of 30.16, a price-to-earnings-growth ratio of 1.78 and a beta of 0.75. Abbott Laboratories has a fifty-two week low of $105.27 and a fifty-two week high of $141.23. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.70 and a quick ratio of 1.24. The stock’s 50-day moving average is $118.46 and its two-hundred day moving average is $125.87.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting the consensus estimate of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The business had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. During the same period last year, the company posted $1.34 earnings per share. The firm’s quarterly revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, equities research analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, February 13th. Stockholders of record on Thursday, January 15th were paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.2%. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.59. The ex-dividend date of this dividend was Thursday, January 15th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 67.74%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.